









Markets
/
Stocks
/
nasdaq-bnr
/

Burning Rock Biotech Ltd

BNR

34.000USD

+3.340+10.91%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

306.98MMarket Cap

LossP/E TTM



Burning Rock Biotech Ltd

34.000

+3.340+10.91%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Burning Rock Biotech Ltd

Currency: USD Updated: 2026-02-06

Key Insights

Burning Rock Biotech Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 63 out of 75 in the Healthcare Providers & Services industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Burning Rock Biotech Ltd's Score

Industry at a Glance

Industry Ranking

63 / 75

Overall Ranking

365 / 4521

Industry

Healthcare Providers & Services

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Burning Rock Biotech Ltd Highlights

StrengthsRisks

Burning Rock Biotech Ltd is a Company principally engaged in developing and providing cancer therapy selection tests. The Company operates three businesses, including central laboratory business, in-hospital business and pharma research and development services. Central laboratory business mainly includes the sales of its cancer therapy selection test to individual patient customers. In-hospital business includes the manufacture and sales of reagent kits, as well as the provision of facilitation services for laboratory equipment sold to hospitals. The pharma research and development services include a range of cancer therapy selection test services, analytical validation services and project management services.

Growing

The company is in a growing phase, with the latest annual income totaling USD 71.08M.

Undervalued

The company’s latest PE is -20.91, at a low 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 31.72K shares of this stock.

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Burning Rock Biotech Ltd is 7.66, ranking 42 out of 75 in the Healthcare Providers & Services industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 18.50M, representing a year-over-year increase of 4.43%, while its net profit experienced a year-over-year increase of 52.15%.

Score

Industry at a Glance

Previous score

7.66

Change



Financials

9.84

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

5.65

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

8.67

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.98

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.15

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Burning Rock Biotech Ltd's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Burning Rock Biotech Ltd is 7.18, ranking 36 out of 75 in the Healthcare Providers & Services industry. Its current P/E ratio is -20.91, which is -101.87% below the recent high of 0.39 and -20.76% above the recent low of -25.26.

Score

Industry at a Glance

Previous score

7.18

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 63/75

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

No earnings forecast score is currently available for Burning Rock Biotech Ltd. The Healthcare Providers & Services industry's average is 7.58.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Burning Rock Biotech Ltd is 8.98, ranking 16 out of 75 in the Healthcare Providers & Services industry. Currently, the stock price is trading between the resistance level at 42.90 and the support level at 23.93, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.49

Change

1.49

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-1.271

Neutral

RSI(14)

56.010

Neutral

STOCH(KDJ)(9,3,3)

30.073

Neutral

ATR(14)

4.286

High Vlolatility

CCI(14)

-60.741

Neutral

Williams %R

63.149

Sell

TRIX(12,20)

1.899

Sell

StochRSI(14)

29.337

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

34.148

Sell

MA10

34.484

Sell

MA20

32.361

Buy

MA50

25.039

Buy

MA100

17.877

Buy

MA200

11.456

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Burning Rock Biotech Ltd is 3.00, ranking 60 out of 75 in the Healthcare Providers & Services industry. The latest institutional shareholding proportion is 46.56%, representing a quarter-over-quarter decrease of 1.52%. The largest institutional shareholder is James Simons, holding a total of 31.72K shares, representing 0.35% of shares outstanding, with 0.06% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Northern Light Venture Capital

1.05M

Kynam Capital Management LP

994.88K

Lyfe Capital

833.84K

CRCM L.P.

486.43K

+119.53%

China Merchants Bank Co Ltd

462.99K

Quantum Boundary Holdings Ltd

353.92K

+10637.83%

Amova Asset Management Americas, Inc

45.55K

Amova Asset Management Co., Ltd.

34.84K

-20.68%

Renaissance Technologies LLC

Star Investors

31.72K

BofA Global Research (US)

29.18K

-0.34%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Providers & Services domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Burning Rock Biotech Ltd is 1.68, ranking 68 out of 75 in the Healthcare Providers & Services industry. The company's beta value is 1.34. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.